Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Feb
24
Today In Oncology
Multiple Myeloma FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
New Biomarker May Predict Chemotherapy Response in Patients With Triple-Negative Breast Cancer
Acral Melanoma Ancestry and Genetics Impact Outcomes
Inequalities in Use of Minimally Invasive Surgical Resection in Colon Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo